Axsome’s solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile.
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal
Where Today's News Shapes Tomorrow
